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The  Fourier-transform  mid-infrared  spectroscopy  (FTIR)  technique  has not  been  used  for  diabetes  diag-
nosis  so  far  in  clinical  practice.  We  attempted  to  predict  non-invasively  blood  hemoglobin  A1c (HbA1c)
levels  by FTIR  to enable  evaluation  and  screening  for diabetes.  Twenty  eight  patients  from  age  20s  to  80s,
14  males  and  14  females,  with  and  without  diabetes,  were  examined  in  hospital  as  a pilot study,  and  their
biochemical  data  were  analyzed  with  infrared  (IR)  spectral  data  of the lip  surface  by  FTIR  spectroscopy.
Some  IR  peaks  of  lip surface  had  signiﬁcant  correlations  with  blood  glucose  and  HbA1c  levels.  Among
several  peaks  in the  spectra  of lip,  peaks  at around  1300–1400  cm−1 discriminated  groups  with higherTIR–ATR
iabetes screening
ip
emoglobin A1c (HbA1c)
dvanced  glycation end products (AGEs)
or  lower  HbA1c  levels,  suggesting  the  observation  of  lip surface  advanced  glycation  end-products  with
carboxymethyl  group.  The  application  of  partial  least  squares  (PLS)  regression  analysis  to  the  correlation
between  HbA1c  levels  and  lip  FTIR  spectra  resulted  in highly  signiﬁcant  prediction  of  HbA1c  values  for
the  subjects.  Comparison  of some  IR  peaks  with  predicted  HbA1c  values  served  to remove  false-negative
data  effectively.  This  study  with  FTIR  technique  proposed  here  was  effective  for screening  of  diabetes
patients  with  higher  HbA1c  levels.
 . Introduction
Diagnosis of diabetes mellitus is performed routinely by chem-
cally measuring blood glucose and glycated hemoglobin A1c
HbA1c) or glycated albumin serum levels with a blood sample
ollected by venous injection. The near-infrared spectroscopy tech-
ique may  represent a non-invasive method [1,2]. Many proposals
or non-invasive measurement of blood glucose level have been
ublished in the last 15 years, including electrical and optical meth-
ds using near-IR, mid-IR with Fourier-transform spectroscopy,
aser Raman scattering, and various types of ﬂuorescence spectros-
opies [3–6].
FTIR  spectral analysis reveals differences in several major
etabolic components, lipids, proteins, glucose, thiocyanate and
arboxylate, and can clearly distinguish healthy and diseased saliva
7]. For example, the lipid ester band at 1735 cm−1 was more
ntense in diabetic saliva, while the bands located at 1400 and
582 cm−1 were less intense [7].
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The development of non-invasive measurement of the blood
glucose level would be useful for diagnosis of diabetes and
screening, and would promote clinical monitoring and permit
better management of the disease. It was reported [8] that self-
monitoring of blood glucose performed seven or more times per
week reduced the lifetime incidence of diabetes-related compli-
cations and that periodic testing (1 or 2 times per week) may be
cost-effective.
Heise and Marbach [3] used FTIR–ATR (attenuated total reﬂec-
tion) to characterize the outermost layer of human oral mucosa to
monitor the blood glucose concentration, and recently Heise and
his colleagues also reported [9] that near infrared spectra of differ-
ent skin regions were recorded for comparison with clinical blood
analysis data and further patient information allowing classiﬁca-
tion into diabetics and non-diabetics.
We have now attempted to evaluate glycation products in
the skin layer harboring advanced glycation end products (AGEs),
which might be more prevalent in skin cells of diabetics. Glycated
-hemoglobin, -albumin, -collagen, and AGEs all were increased
in diabetes patients [8,10,11]. We report a new non-invasive
Open access under CC BY-NC-ND license.screening technique using FTIR–ATR with a novel adaptor for spec-
troscopy of human lip (lower vermilion portion, not including
mucosa) of diabetes patients from ages 20s to 80s, and predict the
HbA1c values with removal of false negatives.
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Table 1
Baseline characteristics of patients including diabetes and non-diabetes.
Diabetes group (n = 18) Non-diabetes group
(n = 10)b
HbA1c (%)a 6.6–10.8 (8.0 ± 1.2) 5.3–6.3 (5.8 ± 0.4)
Blood glucose (mg/dL) 71–285 (159.5 ± 67.8) 83–144 (104.6 ± 21.6)
Age (years) 27–82 (60.4 ± 16.4) 31–80 (66.5 ± 15.4)
Sex  (% male) 10 (55.5) 4 (40.0)
Measurements were performed from 2 March to 5 April, 2010 in Department of
Clinical Laboratory, Gifu University Hospital.
a The value for HbA1c(%) (with mean ± SD) is estimated as an NGSP equivalent
value (%) calculated by the formula HbA1c (%) = HbA1c(JDS)(%) + 0.4%, consider-
ing  the relational expression of HbA1c(JDS)(%) measured by the previous Japanese
standard substance and measurement methods as described in the method section
[35].
b The non-diabetes group includes temporally 1 diabetes patient with lowered
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.1. Materials and subjects
The measurement of subjects was performed once a week
etween March 5 and April 2, 2010 at Gifu University Hospital,
ifu, Japan. In total, 28 patients were recruited including 18 with
iabetes. The study protocol was approved by the ethics review
ommittee of the Graduate School of Medicine, Gifu University and
as in accordance with the principles described in the Declaration
f Helsinki. All participating patients gave their written informed
onsent prior to measurement.
Carboxymethyllysine and carboxymethylarginine were pur-
hased from Funakoshi, Japan. Carboxymethylated dipalmi-
oylphosphatidylethanolamine (DPPE) was synthesized from
tandard DPPE (purchased from Sigma, USA) in our laboratory
ccording to the method of Utzmann and Lederer [12], and the
roduct was conﬁrmed by FTIR. Other routine chemicals were
btained commercially. Wet  cotton papers (Bioré®) for wiping
ips were purchased from Kao Co., Japan. Twenty-eight subjects
ncluding diabetes patients and non-diabetes subjects are summa-
ized in Table 1. The value for HbA1c (%) of subjects is estimated
s a National Glycohemoglobin Standardization Program (NGSP)
alue calculated by 0.4% + HbA1c (JDS) [13] measured by HPLC
ethod in the Clinical Laboratory of Gifu University Hospital. The
easurement by FTIR was  performed in the out-patient physicalxamination room of Gifu University Hospital before noon (from 9
.m. to 11 a.m.). Clinical data of the subjects obtained in the hospital
ere managed by the physician (M.Y.), who is diabetes specialist
ertiﬁed by the Japan Diabetes Society.
ig. 1. Correlational analyses between blood data (glucose and HbA1c) and lip skin IR p
n  = 24) after four outliers are removed, where “Gluc now” means the serum glucose lev
bA1c  vs. “Gluc(prev)” is shown, where “Gluc(prev)” means the serum glucose level me
a)  and (b), the correlation coefﬁcients (R = 0.64 and 0.63, respectively) are nearly the sam
he  spectra of all subjects (n = 28), showing peak positions at 1550, 1311, 1296, 1080, 105
hown.  For lip measurement, the IR peak ratio is [1311] × [1080]/[1296] × [2960]/[1550].HbA1c level (6.2%) by medication, and this grouping is maintained for purpose of
HbA1c prediction analysis.
2.2. Measurement of infrared spectra
Fourier-transform infrared spectroscopy with attenuated total
reﬂection adaptor (FTIR–ATR) (TravelIR; SensIR (now Smith Detec-
tion Inc.), USA) was used for measurement of IR spectra of lip
and skin of human subjects; we refer to this IR system as CISME
(Corneum Infrared Spectral analysis for Metabolic Experiments),
as previously reported [14], and a specially designed ATR adaptor
was made by the ﬁnancial support of JST (Japan Science and Tech-
nology Agency, Tokyo, Japan) and ST Japan Co., (Tokyo, Japan). The
lip and face (chin only) skin of the patients was evaluated with this
FTIR–ATR device and in this report lip data was presented.
eak ratios of subjects. In (a) of (A), “Gluc now” data vs. lip IR peak ratios is shown
el measured on the day of FTIR measurement (“Glucose on the day”); in (b) of (A),
asured previously (n = 28; nearly 1-month ago of the FTIR measurement). In both
e. In (B), lip FTIR spectrum in the second derivative form is shown after averaging
0, and 1030 cm−1, and also the standard deviation plots at each wave number are
S. Yoshida et al. / Journal of Pharmaceutical and Biomedical Analysis 76 (2013) 169– 176 171
Table  2
Summary of PLS statistical data for averaged spectra.
Statistics terms Data
1. Calibration windows (wave
number)
968.6–1053.5, 1161.6–1184.7,
1219.5–1327.5, 1547.5–1655.5 (cm−1)
2.  Cross-validation No
3. SEC (standard error of
calibration)
0.362
4.  RMSEC (the same as RMSEP) 0.335
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y5. R (correlation coefﬁcient of
calibration)
0.985
The CISME–ATR probe system was set on a table and the subject
r patient was asked to sit on a chair facing it. The lip (lower vermil-
on portion), after cleaning off saliva or other stains on it by subject’s
wn hand (cleaning level could be checked by FTIR spectrum), was
ttached closely on the diamond ATR probe surface (with 2 mm
iameter) and the measurement of FTIR was carried out twice for
early 40 s with 8 cm−1 resolution and 64 spectral accumulations in
ne measurement, and the two spectral data for one subject were
veraged and used in the PLS analysis described below. The second
erivative spectrum was obtained with 9 point derivatization by
avitzky–Golay method (using GRAMS-AI software; Thermo Inc.,
SA). This type of measurement of IR spectra of skin was  reported
reviously [14,15].
.3. Correlation and PLS regression analyses
The correlation analyses were performed with Excel software
Microsoft, USA) using Pearson’s product moment correlation coef-
cient (R) and in some case its squared value (R2) for the strength of
he relationship, and the signiﬁcance of the relationship expressed
n the probability level (p).
Partial least squares (PLS) regression analyses for FTIR spectra
nd serum data of patients were done using commercial soft-
are (Panorama; LabCognition, Analytical Software GmbH & Co.
G, Germany). Initially, various calibration conditions were used
o evaluate calibration data, cross-validation process, estimation
f component number using PRESS (predictive residual sum of
quares) change, and several wave number regions (spectral inter-
als (windows)) to maximize its ﬁt to non-calibrated data set. A
even-calibrated data set was used for validation of other data; it
as important not to over-ﬁt for the calibrated data in PLS model-
ng by using 3 of the minimum component (factor) number and four
pectral windows (the areas centered around 1050, 1150, 1300, and
550 cm−1). The detailed statistical data were presented in Fig. 4,
nd here one spectral data for a person was obtained by averaging
f two spectral data for one person measured successively within
 min. The validation statistics was shown in Table 2. The setting of
alibration spectral windows was critical.
.4. Method validation
For actual application of the present FTIR–ATR technique to
linical diagnosis and screening, it is necessary to validate the tech-
ique properly. Although the present paper aims to describe a pilot
est of a new technique, not just a clinical application, we  describe
ere brieﬂy the selectivity or accuracy, repeatability, intermediate
recision, linearity, range of concentration, and quantitation limit
f the FTIR–ATR method in the application to medical and biological
aterials, which are presented in Section 4.4.. Results
Fig. 1(A) shows the results of basic correlation anal-
ses between serum glucose levels (data on the IRFig. 2. Correlations with ages of subjects for IR ratio (A) and for serum glucose
(gluc(now); (B)). In both cases no positive correlations (R = −0.37 and −0.21) are
shown. In (A) the IR ratio is [1311] × [1080]/[1296] × [2960]/[1550].
measurement day) and IR peak ratios for speciﬁc wave num-
bers ([1311] × [1080])/[1296] × ([2960]/[1550]) of lip of subjects
(n = 24) (a) after removal of four outliers, and also the correlation
between serum glucose levels (nearly 1-month-ago data) and
HbA1c levels (data on the IR measurement day) for all subjects
(n = 28) (b). In both cases some scatters of plots were observed with
correlation coefﬁcient (R) at around 0.6 (p < 0.001), suggesting
that glucose levels were quite variable although HbA1c levels
were thought to be stable for individuals. Fig. 1(B) shows the
second derivative FTIR spectrum (averaged for IR spectral data
of all subjects) of lip and the plot of standard deviation for each
wave number. In the case of lip measurement, we adopted IR peak
ratio ([1311] × [1080])/[1296] × ([2960]/[1550]) in the correlation
analysis after many trials to ﬁnd suitable peak combinations for
higher and signiﬁcant correlation coefﬁcients between blood
data and IR peak ratios. Here, [1311] marks the intensity of IR
peak in the second derivative form at 1311 cm−1. This ratio may
imply [glycan-related peak at 1080 cm−1] × [methyl/amide II
ratio] × [glycated factor ratio [1311]/[1296]].
Fig. 2 shows the correlation between ages and IR ratios (A) or
glucose levels (B), indicating no signiﬁcant correlation with ages of
the subjects under investigation. As the range of ages of subjects
were wide enough (from 20s to 80s), these data may  indicate that
a factor originated from just aging can be excluded in the correla-
tion analysis between IR ratios of lip surface and glucose levels of
subjects, and the IR ratio adopted in this analysis may be suitable
for prediction of glucose levels of the subjects.
Fig. 3 shows the averaged second derivative IR difference
spectrum between the higher (>6.5%) HbA1c group and the
lower (<6.5%) HbA1c group (higher minus lower A1c groups
with lip difference spectrum denoted by LDS) in (A) includ-
ing the region at around 1280–1500 cm−1, and the spectrum of
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Fig. 3. Lip FTIR spectra and correlations with some carboxylmethylated compounds. FTIR spectrum of subjects’ lips in subtracted form denoted by LDS (Lip Difference
Spectrum in second derivative form; “Higher = spectrum for higher (≥6.5%; Higher-A1c) HbA1c” minus “Lower = spectrum for lower (<6.5%; Lower-A1c) HbA1c”) is shown in
(A),  and the wave number region marked by a horizontal rectangle bar is between 1500 and 1280 cm−1. In (B) the second derivative FTIR spectrum is shown for summed CMA
and  CM-DPPE authentic spectra in 1:1. In (C) and (D) the correlations are shown between the intensity of the second derivative LDS spectrum at each wave number and that
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MA  spectra are signiﬁcant (R = 0.51 and 0.59, respectively). In (E) the correlation b
s  shown and highly signiﬁcant (R = 0.75).
um of authentic carboxymethyl compounds (CM-DPPE and CMA;
:1) in (B), where CM-DPPE and CMA  are carboxymethylated
ipalmitoylphosphatidylethanolamine [16] and carboxymethy-
arginine, respectively, and both are AGEs. Some AGEs including
arboxymethyllysine were detectable on the skin [17,18]. CMA
howed IR peaks at 1266, 1311, 1344 and 1394 cm−1, originating
rom the carboxylic group. Similarity of the lip difference spectral
attern (LDS) with some AGEs IR spectra was evaluated by corre-
ation analyses (Fig. 3(C)–(E)) for those second derivative spectralumber between 1500 and 1280 cm . The correlations of LDS with CM-DPPE and
n LDS spectral intensity and the summed spectral intensity of CMA plus CM-DPPE
(1280–1500 cm−1) patterns. Especially the LDS pattern was  sim-
ilar to CMA  (C) and CM-DPPE (D), and more signiﬁcantly similar
to or highly correlated (R = 0.75) with the summed spectrum of
CMA  plus CM-DPPE (E). However, this LDS pattern was  not much
similar to carboxymethyllysine (not shown). These results indicate
that lip IR spectra of higher HbA1c group as compared with lower
HbA1c group contained signiﬁcantly similar IR patterns in the range
between 1280 and 1500 cm−1 to some AGEs compounds, i.e. CM-
DPPE plus CMA. Actually we  could detect CM-DPPE and CMA in the
S. Yoshida et al. / Journal of Pharmaceutical and Biomedical Analysis 76 (2013) 169– 176 173
Fig. 4. Correlations between the measured HbA1c (%) values of subjects and the predicted HbA1c values with PLS analysis for averaged IR data (A). The correlation coefﬁcient
(R  = 0.822) is much higher than that for one-shot IR spectral data, and highly signiﬁcant. Three outliers are removed. The insetted ﬁgures are calibrated data plots for 7 data
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1ith  the PLS program (A1) and non-calibrated data plots (A2). The correlation for no
hange of PRESS values is shown in the calibration process.
xtract of tape-stripped face skin SC by mass spectrometric tech-
ique (not shown in this paper and will be reported in elsewhere).
Fig. 4(A) shows the correlation between “measured” and “pre-
icted” HbA1c values obtained by partial least squares (PLS)
egression analysis for the averaged spectra of two IR spectra per
ne subject (n = 25), and in this case 3 outliers (two patients and
ne non-diabetic subject) were found and removed. The (squared)
orrelation coefﬁcient was R = 0.82 (R2 = 0.676) with p < 0.00001,
uggesting signiﬁcantly high correlation. A calibration data set for
 subjects was used (insetted ﬁgure A1). The non-calibrated data
et shown in the insetted ﬁgure A2 showed signiﬁcant correlation
ith R = 0.621 (p < 0.01, n = 18). The PLS statistical data was  sum-
arized in Table 2, where the spectral windows for calibration
ere used for 968.6–1053.5, 1161.6–1184.7, 1219.5–1327.5, and
547.5–1655.5 cm−1. The change of PRESS for 4 factors in the cali-
ration process was shown in Fig. 4(B) and actually 3 factors were
sed for calibration. It was noticed that the prediction power was
ore enhanced by using averaged spectral data than using one-
hot spectral data (not shown). Actually SEC and RMSEC (or RMSEP)
ere around 0.35, which was much smaller than that for one-shotpectral data using cross-validation PLS method with SEC (or SECCV)
nd RMSEC (or RMSECCV) at around 0.8. Using averaged spectral
ata, 87.5% of diabetes patients were suitably predicted (14 out of
6 patients) and the false negative data points were two  in 25.brated data in A2 is signiﬁcant (R = 0.62; n = 18, p < 0.01). In (B) the factor-dependent
PLS-based prediction of HbA1c values with lip FTIR spectra as
described above seems valuable for screening of diabetes patients
even for small size of group (n = 25 in all 28 subjects), and all
subjects were recruited nearly freely in the hospital during the
measurement period (4 days in a month, every Friday). However, it
was necessary to discriminate false negative data for the diabetes
patients as much as possible from the predicted data set obtained
by PLS method.
We then attempted to determine the relationship between
predicted HbA1c level and the second derivative IR intensity at
968 cm−1 (“delta968”). We  reported previously that delta968 was
correlated with the amount of lipid hydroperoxide on the lip sur-
face [14]. There were 2 false-negative data points when the critical
HbA1c level was set to 6.5%. The X–Y plots for the predicted HbA1c
values and delta968 values were obtained as shown in Fig. 5(A).
The zone with the predicted HbA1c values below 6.5% and delta968
values over 8 ×10−5 contained 2 diabetes patient data points (false-
negative data) and 3 non-diabetic subject data points with HbA1c
below 6.5%. In this case, the screening and detection efﬁciency of
diabetes patients was  87.5% (14/16) and the false negative rate was
12.5% when only PLS method was  used for averaged IR data. This
detection efﬁciency was  increased to 100% when delta968 values
were included for analysis. The effectiveness in using delta968 cri-
terion at 8 × 10−5 was also observed for one-shot (not averaged) IR
174 S. Yoshida et al. / Journal of Pharmaceutical and Biomedical Analysis 76 (2013) 169– 176
Fig. 5. Correlation plots between the predicted HbA1c values obtained by PLS analysis and delta968 values of lips of subjects (n = 25 after removal of three outliers) (A). The
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round  968 cm−1.
ata, and in this case the detection efﬁciency 78% was  increased to
00% when delta968 values were included for analysis.
Fig. 5(B) shows the second derivative LDS in the range between
50 and 1000 cm−1, and the negative peak is noticed at round
68 cm−1 which is a marker peak of trans double bonds in
nsaturated fatty acids [14] which may  be formed mainly after
eroxidation reaction of fatty acids.
. Discussion
.1. Role of AGEs
Up to now, most self-monitoring devices for blood glucose are
nvasive, and a large amount of blood is required to measure HbA1c
evels. Some reports suggest that skin auto-ﬂuorescence (AF) is cor-
elated with diabetes duration (p < 0.05) and HbA1c levels (p < 0.05)
19,20]. It is also reported that high-doses of salicylates, vitamins
 and E, and severe iron deﬁciency are interfering substances for
bA1c assay and that blood conditions such as hemolytic ane-
ia  may  proportionally decrease HbA1c [21,22]. There is a report
23] that linear regression analysis indicates weak relationships
mong different assessments of HbA1c and skin AF at follow-
p, and that the HbA1c assessment over years poorly predictedquared off by dashed lines, and contained only 2 patients and easily discriminated.
at less than 8 × 10−5 is 3. In (B), the second derivative LDS is shown in the region at
the change in skin AGEs level measured by skin AF. For exam-
ple, carboxymethyllysine, one of the major AGEs in skin [24,25],  is
not ﬂuorescent, and may  not contribute to the auto-ﬂuorescence
in AGEs. On the other hand, carboxymethyl-ethanolamine was
reported [26] as a biomarker of phospholipid modiﬁcation during
the Maillard reaction in vivo, and recently it was reported [27] that
Amadori-glycated phosphatidylethanolamine (Amadori-PE) accu-
mulates in the plasma of diabetic humans and animals, suggesting
that it might be a useful marker for hyperglycemia, particularly
in the early stages of diabetes. On the other hand, the amount of
carboxymethylated phosphatidylethanolamine (CM-PE) in plasma
of diabetes patients was  not different from healthy controls [16],
however, there was  no data available about the amount of CM-PE
in skin or SC.
4.2. Quantitation limits of this technique
As shown in Fig. 3, we could detect carboxymethyl compounds
on the surface of lip SC, and especially CM-PE and CMA  may  be
plausible major candidates which contributed signiﬁcantly as spec-
tral components of higher HbA1c group of subjects. These AGEs
on the lip or skin surface also may  contribute the indirect assay of
HbA1c values using FTIR spectra of lip. Originally CMA  was found in
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ollagen as acid-labile AGEs [28]. Diabetes patients had more CMA
n serum than normal controls (124 ng/mL vs. 85 ng/mL) [29]. There
as no report describing the actual concentration of CMA  or other
GEs in skin or SC, however, carboxymethyllysine was  reported
o be present at around 0.5 nmol/mg skin collagen or more [30],
nd so other carboxymethylated compounds may  be also present
n nmol or more order per mg  skin tissue totally, suggesting the
resence of pmol to nmol order of those AGEs in the measured
rea of skin SC. In this case FTIR–ATR technique is suitable to detect
his much of compounds present on SC, and actually FTIR–ATR
ould detect 38 pmol of CMA  on the ATR probe with measurable
bsorbance at around 1400 cm−1 (not shown in this paper).
.3. Change of biomolecules on the lip
We have found blood glucose- and HbA1c-dependent
hanges of IR peak intensities including absorbance at around
300–1400 cm−1 in lip. We  reported previously that fatty acid
etabolism in human could be detected through lip surface
easurement by FTIR–ATR,[14] which suggests that AGEs may  be
lso transported through lip SC more rapidly than through other
ormal face skin.
The lipid lamellar structure [31] in intercellular space of SC of
uman lip may  contribute to this rapid recovery of materials on
he surface (with in-ﬂow of lamellar components to lip surface)
nd may  protect against dryness of lip. This lamellar structure may
ontain both lipophilic and aqueous phases, including water, ionic
nd glycated materials. Trans-dermal ionic materials ﬂow may
e associated with the lipid lamellar dynamics [32]. This ﬂow of
ntercellular lipids and aqueous phases in lamellae from deeper
pidermal layers to the outermost surface of SC might well rapidly
ransport molecules including AGEs from the capillary blood or
ermal cells.
In this paper we have reported the usefulness of FTIR–ATR tech-
iques for the screening of high HbA1c levels in diabetes mellitus.
oreover, diabetes patients may  have high risk for complications
uch as dyslipidemia in most cases, and the present FTIR–ATR
echnique can detect changes of fatty acids in blood through mea-
urement of human lip and oral mucosal tissues in vivo [14,33].
.4. Validation of FTIR–ATR technique
The selectivity and accuracy of FTIR are primarily based on
he Fourier transform technology in infrared spectroscopy and the
reat information of the functional groups of biomolecules could
e selectively given by this method and the accuracy of wave
umbers is generally quite conﬁdent with using the laser tech-
ology to adjust wave numbers. The accuracy (or precision) of
ampled FTIR data (n = 12; 5 or 10 min  interval in repeated measure-
ents) is denoted by MAPD (Mean Absolute Percentage Deviation
or Difference)) value, and for ﬁxed biomolecules (actually dried
erum) MAPD is 0.126% using the intensity ratio at 1050 cm−1 and
030 cm−1, and for lip tissue in vivo it is 7.94%. This relatively
arge deviation in the alive tissue seems to be caused by periodic
hanges of lip surface biomolecules appeared with nearly 20 min
eriodicity. MAPD in the prediction of HbA1c of the patients shown
n Fig. 4 is 8.93% (n = 25; duplicated and averaged FTIR data were
sed for PLS prediction). The repeatability is denoted by CV (coef-
cient of variation) values, and actually the CV is 0.146% in the
ntensity ratio at 1050 cm−1 and 1030 cm−1 for measurement of
ried serum containing various biomolecules when measured by
TIR–ATR with the present CISME adaptor at stable state, and is
.197% when measured within 1 h just after starting of the machine.
he intermediate precision is validated using the same measure-
ent system for samples in different seasons, months, week days,
lock times, and using four different operators for past 3 years, and
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for ﬁxed biomolecules no large deviations are observed (within
0.2% of CV). The linearity was described previously [34], and the
intensity ratio [2850 cm−1]/[1650 cm−1] in FTIR–ATR had a linear
relationship for triglyceride/protein ratio (n = 9, R = 0.981) in the
range between 0.3 mg/mg and 1.5 mg/mg. The range of concen-
tration and quantitation limit are partly described above in this
discussion section, and actually 38 pmol of CMA  could be detected
by FTIR–ATR at 1400 cm−1 (the second largest peak of CMA) with
signal-to-noise ratio >10, and approximately 20 pmol of CMA  in
0.3 L may  be detected practically as a lower limit. The lower quan-
titation limit of triglyceride measured by FTIR–ATR is nearly 5 pmol
in 0.3 L loaded on the ATR probe.
5. Conclusions
FTIR–ATR technique may have a potential to measure and screen
metabolic (glycemic and lipidomic) disregulation status at once
in vivo, leading to rapid and non-invasive diagnosis of metabolic
syndrome.
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